Integrative treatment of herbal medicine with western medicine on coronary artery lesions in children with Kawasaki disease
Choi J, Chang S, Kim E, Min SY
Free full text
BACKGROUND Kawasaki disease (KD) is a major cause of coronary artery lesions (CALs) in children. Approximately 10% to 20% of children treated with intravenous immunoglobulin are intravenous immunoglobulin-resistant. This study evaluated the efficacy and safety of adding herbal medicine to conventional western medicines versus conventional western medicines alone for CALs in children with KD. METHODS This study searched 9 electronic databases until August 31, 2021. The inclusion criteria were the randomized controlled trials (RCTs) that assessed the CALs in children with KD and compared integrative treatment with conventional western treatments. Two authors searched independently for RCTs, including eligible articles that fulfilled the inclusion criteria, extracted data, and assessed the methodological quality using the Cochrane risk of bias tool. Meta-analysis was conducted using Cochrane Collaboration's Review Manager 5.4 software. The effect size was presented as the risk ratio (RR), and the fixed-effect models were used to pool the results. RESULTS The finally selected 12 studies included a total of 1030 KD patients. According to a meta-analysis, the integrative treatment showed better results than the conventional treatment in the CAL prevalence rate (RR = 2.00; 95% confidence interval [CI], 1.49-2.71; P < .00001), CAL recovery rate (RR = 1.27; 95% CI, 1.05-1.54; P = .02), and total effective rate (RR = 1.17; 95% CI, 1.11-1.23; P < .00001). Only 2 studies referred to the safety of the treatment. The asymmetrical funnel plot of the CAL prevalence rate indicated the possibility of potential publication bias. CONCLUSIONS This review found the integrative treatment to be more effective in reducing the CAL prevalence rate and increasing the CAL recovery rate and total effective rate in KD patients than conventional western treatment. However, additional well-designed RCTs will be needed further to compensate restrictions of insufficient trials on safety, methodological quality, and publication bias.
Meta-analysis of platelet-rich plasma therapy for anal fistula
Luo Q, Zhou P, Chang S
Journal of cosmetic dermatology. 2022
OBJECTIVE To systematically evaluate the efficacy of platelet-rich plasma (PRP) in treating anal fistula. METHODS PubMed, EMBASE, and Cochrane Library databases were systematically searched for randomized controlled studies (RCTs) and case-control studies published before June 2021 on evaluating the efficacy of platelet-rich plasma (PRP) in treating anal fistula. References of the journals were manually searched for relevant studies. Literature search, screening, data extraction, and bias assessment were carried out by two researcher independently. Stata13.0 and RevMan 5.3 software were used for statistical analysis of the cure rate and recurrence rate of anal fistula. RESULTS A total of 6 case-control studies and 3 RCTs involving 289 patients were included. Meta-analysis showed that the pooled cure rate of all studies was 65% (95% CI 0.53-0.77), p = 0.000, and the pooled recurrence rate of all studies was 12% (95% CI 0.08-0.17). CONCLUSION Platelet-rich plasma is safe and effective in treating anal fistula and should be promoted and further studied in clinical practice.